Criteria for discontinuing or modifying allocated interventions
DIFFERENTIATED THYROID CANCER, PATHOLOGY, ADVERSE EVENTS
Secondary exclusion will be performed for patients in whom final pathology (non-frozen section analysis but defintive pathological evaluation) does not confirm the presence of a differentiated thyroid cancer.In no other instances does this study provide for discontinuing or modifying allocated interventions.Reasons for withdrawal from the trial (study interventions and follow-up) may include:Lost to follow-upWithdrawal of consentDeathIf a patient does not return for a scheduled visit, every effort will be made to contact them. In any case, every effort will be made to document the patient outcome and all attemps should be documented in the corresponding medical file. The investigator will inquire about the reason for withdrawal, request the patient to return for a final visit, if applicable, and follow up with the patient regarding any unresolved adverse events. The early termination final visit should include all assessments listed for the End of Study visit.If the patient withdraws their consent for the study, no further study-specific evaluations will be performed, and no additional data will be collected. The sponsor may retain and continue to use any data and samples collected before such refusal except in case of patient opposition. Any opposition will be transmitted by the investigator to the sponsor without undue delay.